This three-volume comprehensive treatise provides a full discussion of the landscape of patent law, from threshold questions of patentability through post-grant patent law. It includes a thorough discussion of the enormous changes introduced by the Leahy-Smith America Invents Act. The book explains, in clear English, prosecution rules from the U.S. Patent and Trademark Office (PTO), offers an element-by-element analysis of areas of law that form the basis of common PTO rejections and objections, and provides analysis of major court decisions.
Effectively prepare and process a patent application, protect a client’s patent, or invalidate an infringing one
This treatise provides essential analysis of significant changes to U.S. patent law resulting from decisions of the Supreme Court, the Federal Circuit, and the Patent Trial and Appeal Board and places new substantive discussions in context with existing patent laws and regulations. It also explains prosecution rules from the U.S. Patent and Trademark Office (PTO) and offers an element-by-element analysis of areas of patent law that form the basis of common PTO rejections and objections, which can also be used in litigation in federal court.
The Ninth Edition is updated to analyze and highlight the significance of recent Supreme Court cases on patent issues such as patent-ineligible abstract ideas, patentability of products of nature, claim definiteness, and induced infringement.
The Ninth Edition adds discussion of
The Ninth Edition also covers PTO rules and guidance including “2014 Interim Guidance on Patent Subject Matter Eligibility” under §101 after Alice, Myriad, and Mayo, and “Examination Guidelines for Implementing the First Inventor to File Provisions of the Leahy-Smith America Invents Act” providing for the submission of affidavits or declarations to overcome prior art. It also incorporates important decisions covered in the 2014 Supplement, including the Supreme Court’s decision in Association for Molecular Pathology v. Myriad Genetics Inc., which held that DNA is an unpatentable product of nature, while cDNA is a non-naturally occurring genetic sequence and is patent eligible.
The accompanying searchable electronic appendices offer a comprehensive Cumulative Case Digest with an extensive compilation of precedential language, organized by specific issue, in favor of patentability.
To say that Patent Prosecution is a comprehensive resource both for experienced patent practitioners, as well as new aspirants, is an understatement.
Partner, Cravath, Swaine & Moore LLP; Former Under Secretary of Commerce and Director of the U.S. Patent and Trademark Office
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to firstname.lastname@example.org.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).